An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)

Completed

• Conditions: Colorectal Cancer

• Registration Number: NCT01674907
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Study First Submitted: 2012-08-22
• Study First Submitted QC: 2012-08-27
• Study First Posted: 2012-08-29
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-01
• Last Update Posted: 2016-11-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• Adult patients, >/= 18 years of age
• Histologically confirmed metastatic colorectal cancer without prior chemotherapy in the metastatic setting

Exclusion Criteria

• Contraindications for Avastin according to the locally approved package insert (version 7 April 2006)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical/demographic patient characteristics at baseline	approximately 3 years
Dosage/schedule of 1st-line Avastin	approximately 3 years
Chemotherapy regimens used in clinical practice	approximately 3 years
Duration of treatment	approximately 3 years

Secondary Outcome Measures

Name	Time	Method
Relationship between termination of Avastin treatment and time point of progression	approximately 3 years
Progression-free survival	approximately 3 years